Safety and Efficacy Analysis of Targeted and Immune Combination Therapy in Advanced Melanoma—A Systematic Review and Network Meta-Analysis
International Journal of Molecular Sciences · 28.11.2024 · 25 (23) · 12821
DOI: 10.3390/ijms252312821 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.11.2024. Verfasst von Anna Sára Lengyel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, 1085 Budapest, Hungary. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hungarian National Research, Development and Innovation Office, Hungarian Academy of Sciences, EU Horizon 2020 research and innovation program.
Abstract (Originalsprache)
The combinations of BRAF inhibitor-based targeted therapies with immune checkpoint inhibitors currently represent less common therapeutic approaches in advanced melanoma. The aim of this study was to assess the safety and efficacy of currently available melanoma treatments by conducting a systematic review and network meta-analysis. Four databases were systematically searched for randomized clinical studies that included patients with advanced/metastatic melanoma receiving chemotherapy, immune checkpoint inhibitors, BRAF/MEK inhibitor therapy, or combinations thereof. The primary endpoints were treatment-related adverse events (TRAE), serious adverse events (SAE) of grade ≥ 3 adverse events, therapy discontinuation, progression-free survival (PFS), as well as objective response rate (ORR) and complete response rate (CRR). A total of 63 articles were eligible for our systematic review; 59 of them were included in the statistical analysis. A separate subgroup analysis was conducted to evaluate the efficacy outcomes, specifically in BRAF-positive patients. Triple combination therapy or triple therapy (inhibiting BRAF, MEK and PD1/PDL1 axis) showed significantly longer progression-free survival compared to BRAF + MEK combination therapies (HR = 0.76; 95% CI 0.64–0.9), but similar objective and complete response rates in BRAF-mutated melanoma. This safety analysis suggests that triple therapy is not inferior to combined immune checkpoint inhibitors (ICI) and BRAF/MEK therapies in terms of serious adverse events and therapy discontinuation rates. However, monotherapies and BRAF/MEK combinations showed notable advantage over triple therapy in terms of treatment-related adverse events. Combination strategies including BRAF/MEK-targeted therapies with ICI therapies are effective first-line options for advanced, BRAF-mutant melanoma; however, they are associated with more frequent side effects. Therefore, future RCTs are required to evaluate and identify high-risk subpopulations where triple therapy therapies should be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, 1085 Budapest, Hungary.
- Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary.
- HCEMM-SU Translational Dermatology Research Group, Semmelweis University, 1094 Budapest, Hungary.
- Department of Physiology, Semmelweis University, Tűzoltó Str. 37-47, 1094 Budapest, Hungary.
- Institute for Translational Medicine, Medical School, University of Pécs, 7623 Pécs, Hungary.
- Department of Stochastics, Institute of Mathematics, Budapest University of Technology and Economics, 1111 Budapest, Hungary.
ORCID-Profile: Alzahra Ahmed Mohammed, Máté Krebs, Dezső Csupor, András Bánvölgyi
Förderung
- Hungarian National Research, Development and Innovation Office
- Hungarian Academy of Sciences
- EU Horizon 2020 research and innovation program
Zitieren
APA
Lengyel, A. S., Meznerics, F. A., Galajda, N. Á., Gede, N., Kói, T., Mohammed, A. A., Péter, P. N., Lakatos, A. I., Krebs, M., Csupor, D., Bánvölgyi, A., Hegyi, P., Holló, P., & Kemény, L. V. (2024). Safety and Efficacy Analysis of Targeted and Immune Combination Therapy in Advanced Melanoma—A Systematic Review and Network Meta-Analysis. International Journal of Molecular Sciences, 25(23), 12821. https://doi.org/10.3390/ijms252312821
Vancouver
Lengyel AS, Meznerics FA, Galajda NÁ, Gede N, Kói T, Mohammed AA, et al. Safety and Efficacy Analysis of Targeted and Immune Combination Therapy in Advanced Melanoma—A Systematic Review and Network Meta-Analysis. International Journal of Molecular Sciences. 2024;25(23):12821. doi:10.3390/ijms252312821
BibTeX
@article{Lengyel2024,
author = {Lengyel, Anna Sára and Meznerics, Fanni Adél and Galajda, Noémi Ágnes and Gede, Noémi and Kói, Tamás and Mohammed, Alzahra Ahmed and Péter, Petra Nikolett and Lakatos, Alexandra It and Krebs, Máté and Csupor, Dezső and Bánvölgyi, András and Hegyi, Péter and Holló, Péter and Kemény, Lajos V},
title = {Safety and Efficacy Analysis of Targeted and Immune Combination Therapy in Advanced Melanoma—A Systematic Review and Network Meta-Analysis},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {23},
pages = {12821},
doi = {10.3390/ijms252312821}
}
EUVIMED